Patent No. EP4108671 (titled "Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses Thereof") was filed by Moderna on Oct 3, 2011. The application was issued on Nov 20, 2024.
Modified nucleic acids that reduce innate immune response and enhance protein expression by incorporating nucleoside modifications, such as 1-methyl-pseudouridine, into mRNA sequences. These modifications disrupt binding of major groove interacting partners, enabling efficient translation of therapeutic proteins in cells while minimizing immune activation. The modified nucleic acids can be used to treat various diseases by delivering functional proteins directly to target cells, eliminating the need for viral vectors or gene integration.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Get instant alerts for new documents